Novo Nordisk has announced that its experimental oral treatment for sickle cell disease met both of its primary clinical goals in a late-stage trial, producing results that could offer a new treatment option for a condition that affects an estimated eight million people worldwide.
The drug, Etavopivat, was tested in the HIBISCUS trial across 385 patients aged 12 and older over 52 weeks. Patients receiving the treatment experienced a 27% reduction in vaso-occlusive crises, the severe pain episodes caused by blockages in blood vessels that frequently result in hospitalisation. The median time before a patient experienced their first pain crisis was 38.4 weeks in the treatment group, compared with 20.9 weeks for those on placebo.
The haemoglobin results were also significant. Nearly 49% of patients taking Etavopivat recorded an increase in haemoglobin levels of more than 1g/dL, against 7.2% in the placebo group. Low haemoglobin is a persistent complication of sickle cell disease and contributes to fatigue, organ stress and reduced quality of life.
Sickle cell disease is a genetic disorder in which red blood cells become misshapen and rigid, making it difficult for them to pass through smaller blood vessels. Etavopivat belongs to a class of drugs known as pyruvate kinase-R activators, which work by improving the energy metabolism of red blood cells, extending their lifespan and reducing their tendency to sickle. The drug is taken once daily as a pill, which distinguishes it from some existing therapies that require infusion or injection.
That distinction matters practically. Many patients with sickle cell disease manage the condition across decades, and the tolerability of any long-term treatment is a genuine clinical concern. Novo Nordisk reported that the drug's safety profile in the HIBISCUS trial was consistent with findings from earlier studies, with no unexpected adverse effects emerging at scale.
The company has confirmed it will submit Etavopivat for regulatory approval in the second half of 2026. The drug has already received fast track designation from the US Food and Drug Administration, along with orphan drug designation and rare paediatric disease designation, all of which are intended to accelerate the review process for treatments addressing serious unmet medical need.
Market response was measured. Novo Nordisk shares fell 1% to $40.52 on the day of the announcement, reflecting analyst caution about the competitive environment rather than scepticism about the clinical data. The sickle cell treatment market is becoming more crowded. Gene-editing therapies, including those based on CRISPR technology, have received regulatory approval in recent years and represent a different approach to the disease, one that aims for a functional cure rather than ongoing management. An oral daily treatment and a one-time gene therapy serve different patient populations and healthcare systems, but they will compete for prescribing decisions in markets where both are available.
For patients in lower-income countries, where the burden of sickle cell disease is highest, an oral treatment that does not require specialist infrastructure to administer may prove more accessible than gene-based alternatives. Sub-Saharan Africa carries a disproportionate share of global cases, and treatment options there remain limited. Whether Etavopivat reaches those patients will depend significantly on pricing decisions and access agreements that Novo Nordisk has not yet detailed.
The regulatory submissions expected later this year will determine how quickly the drug becomes available, and in which markets. If approved, it would be the first PKR activator licensed for sickle cell disease, adding a mechanistically distinct option to a treatment landscape that has seen meaningful but uneven progress over the past decade.
